Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts rate Bicara Therapeutics “Moderate Buy” overall: Nine analysts recommend buying the stock, one rates it a strong buy, three recommend holding, and one recommends selling. The average 12-month price target is $32.40, above the reported $24.94 opening price.
• Company insiders have been selling shares: CEO Claire Mazumdar and CFO Ivan Hyep sold shares under pre-arranged Rule 10b5-1 plans, while insiders sold 117,200 shares worth approximately $3.27 million over the past quarter.
• Bicara reported an in-line quarterly loss: The clinical-stage biopharmaceutical company posted a loss of $0.82 per share, matching analyst expectations, and analysts expect a full-year loss of $3.45 per share.

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fourteen analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $32.40.

Several equities research analysts recently commented on BCAX shares. Wall Street Zen raised Bicara Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Sunday, May 24th. Guggenheim initiated coverage on Bicara Therapeutics in a research note on Monday, May 11th. They issued a "buy" rating and a $42.00 price target on the stock. Mizuho lifted their price objective on Bicara Therapeutics from $18.00 to $20.00 and gave the stock a "neutral" rating in a report on Wednesday, August 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Bicara Therapeutics in a report on Monday, July 6th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Bicara Therapeutics in a research report on Wednesday, May 27th.

Insiders Place Their Bets

In other news, CEO Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $27.98, for a total transaction of $279,800.00. Following the transaction, the chief executive officer directly owned 362,152 shares of the company's stock, valued at $10,133,012.96. The trade was a 2.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 12,500 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $27.97, for a total transaction of $349,625.00. Following the completion of the transaction, the chief financial officer owned 129,855 shares of the company's stock, valued at approximately $3,632,044.35. The trade was a 8.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 117,200 shares of company stock worth $3,267,100 over the last quarter. 13.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bicara Therapeutics

Several large investors have recently made changes to their positions in the company. Deutsche Bank AG boosted its stake in Bicara Therapeutics by 0.9% during the fourth quarter. Deutsche Bank AG now owns 128,626 shares of the company's stock valued at $2,165,000 after buying an additional 1,171 shares during the last quarter. Legal & General Group Plc lifted its position in Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock valued at $29,000 after purchasing an additional 1,233 shares during the last quarter. Mariner LLC grew its stake in shares of Bicara Therapeutics by 3.0% in the 4th quarter. Mariner LLC now owns 64,562 shares of the company's stock worth $1,087,000 after buying an additional 1,902 shares in the last quarter. Invesco Ltd. raised its position in shares of Bicara Therapeutics by 13.2% during the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company's stock valued at $157,000 after buying an additional 1,962 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its holdings in shares of Bicara Therapeutics by 16.1% in the 1st quarter. Quantinno Capital Management LP now owns 17,612 shares of the company's stock valued at $350,000 after acquiring an additional 2,447 shares during the last quarter.

Bicara Therapeutics Stock Up 2.7%

BCAX stock opened at $24.94 on Tuesday. The business has a 50 day moving average of $26.24 and a 200 day moving average of $21.90. The firm has a market cap of $1.65 billion, a PE ratio of -8.05 and a beta of -0.75. Bicara Therapeutics has a twelve month low of $10.30 and a twelve month high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting analysts' consensus estimates of ($0.82). On average, research analysts expect that Bicara Therapeutics will post -3.45 earnings per share for the current fiscal year.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source